Findings

What do systematic reviews say?

4,749 questions · 17,858 findings · 1,266 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4,359 · 24.4%GRADE not reported 2,348 · 13.1%Very low 4,634 · 25.9%Low 4,000 · 22.4%Moderate 2,052 · 11.5%High 465 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Berotralstat vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Low

Berotralstat vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.03 [0.88, 1.22]
3 studies · 128 participants
Moderate

C1 esterase inhibitor vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

C1 esterase inhibitor may leads to lower risk of HAE attacks (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.29 [0.16, 0.5]
1 study · 43 participants
Low

C1 esterase inhibitor vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low

C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.14]
1 study · 44 participants
Very low

C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Low

Avoralstat vs placebo

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 134 participants
Low

C1 esterase inhibitor vs placebo or active control

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

C1 esterase inhibitor vs placebo or active control

Adverse events (during · children or adults with Types I or II HAE

C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.03 [0.84, 1.27]
1 study · 44 participants
Moderate

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 71 participants
Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.54 [0.09, 3.1]
1 study · 71 participants
Very low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.05 [0.78, 1.42]
1 study · 71 participants
Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low